Glofitamab
A bispecific T-cell engaging antibody that simultaneously binds to CD20 on B-cell lymphoma cells and CD3 on T-cells, bringing immune cells into direct contact with cancer cells to trigger their destruction. It is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after multiple prior therapies. Cytokine release syndrome is a significant but manageable side effect requiring careful clinical monitoring.
Lĩnh vực điều trị
Cơ chế tác dụng
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
A bispecific T-cell engaging antibody that simultaneously binds to CD20 on B-cell lymphoma cells and CD3 on T-cells, bringing immune cells into direct contact with cancer cells to trigger their destruction. It is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after multiple prior therapies. Cytokine release syndrome is a significant but manageable side effect requiring careful clinical monitoring.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Glofitamab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298092. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="glofitamab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/glofitamab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/glofitamab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/glofitamab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="glofitamab"></drugfyi-drug>